Advertisement

Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update

  • Dirk P. Dittmer
  • Blossom Damania
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 177)

Abstract

In this book chapter, we review the current knowledge of the biology and pathogenesis of Kaposi’s sarcomaassociated herpesvirus (KSHV). We describe the lifecycle of KSHV, the cancers associated with this virus, as well as current treatment modalities.

Notes

Acknowledgements

Due to space restrictions, we regret that we had to omit many important references. BD is a Leukemia & Lymphoma Society Scholar. DPD is a member of the AIDS malignancies clinical trials consortium (AMC). Please note that this chapter is an updated version of the chapter we wrote for the previous version of this book (AIDS-Associated Viral Oncogenesis, 2007. Springer Press. Editor: Craig Meyers).

References

  1. 1.
    Ablashi DV, Chatlynne LG, Whitman Jr JE, Cesarman E Jr (2002) Spectrum of Kaposi’s sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. Clin Microbiol Rev 15(3):439–464CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Anders P, Bhende PM, Foote M, Dittmer DP, Park SI, Damania B (2015) Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma. Leuk Lymphoma 56(1):263–266.  https://doi.org/10.3109/10428194.2014.917639CrossRefPubMedGoogle Scholar
  3. 3.
    Anders PM, Zhang Z, Bhende PM, Giffin L, Damania B (2016) The KSHV K1 protein modulates AMPK function to enhance cell survival. PLoS Pathog 12(11):e1005985.  https://doi.org/10.1371/journal.ppat.1005985CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S, Silverstein RL, Rafii S, Mesri EA (2003) Kaposi’s sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3(2):131–143CrossRefPubMedGoogle Scholar
  5. 5.
    Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S, Crescenzi B, Wolf DG, Schulz TF, Torelli G (2003) Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 9(5):554–561CrossRefPubMedGoogle Scholar
  6. 6.
    Beral V, Peterman TA, Berkelman RL, Jaffe HW (1990) Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335(8682):123–128CrossRefPubMedGoogle Scholar
  7. 7.
    Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B (2010) Dual inhibition of PI3 K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 115(22):4455–4463.  https://doi.org/10.1182/blood-2009-10-251082CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Bower M, Nelson M, Young AM, Thirlwell C, Newsom-Davis T, Mandalia S, Dhillon T, Holmes P, Gazzard BG, Stebbing J (2005) Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol 23(22):5224–5228.  https://doi.org/10.1200/JCO.2005.14.597CrossRefPubMedGoogle Scholar
  9. 9.
    Brayfield BP, Kankasa C, West JT, Muyanga J, Bhat G, Klaskala W, Mitchell CD, Wood C (2004) Distribution of Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 in maternal saliva and breast milk in Zambia: implications for transmission. J Infect Dis 189(12):2260–2270CrossRefPubMedGoogle Scholar
  10. 10.
    Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, Tirelli U (2005) Kaposi’s sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn 7(1):17–27CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103(5):1632–1634CrossRefPubMedGoogle Scholar
  12. 12.
    Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS- related body-cavity-based lymphomas. N Engl J Med 332(18):1186–1191CrossRefGoogle Scholar
  13. 13.
    Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266(5192):1865–1869CrossRefGoogle Scholar
  14. 14.
    Chen W, Sin SH, Wen KW, Damania B, Dittmer DP (2012) Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog 8(11):e1003048.  https://doi.org/10.1371/journal.ppat.1003048CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Cheng F, Pekkonen P, Laurinavicius S, Sugiyama N, Henderson S, Gunther T, Rantanen V, Kaivanto E, Aavikko M, Sarek G, Hautaniemi S, Biberfeld P, Aaltonen L, Grundhoff A, Boshoff C, Alitalo K, Lehti K, Ojala PM (2011) KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host Microbe 10(6):577–590.  https://doi.org/10.1016/j.chom.2011.10.011CrossRefGoogle Scholar
  16. 16.
    Civati G, Busnach G, Brando B, Broggi ML, Brunati C, Casadei GP, Minetti L (1988) Occurrence of Kaposi’s sarcoma in renal transplant recipients treated with low doses of cyclosporine. Transplant Proc 20(Suppl 3):924–928PubMedGoogle Scholar
  17. 17.
    Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97(6):425–432CrossRefGoogle Scholar
  18. 18.
    Connick E, Kane MA, White IE, Ryder J, Campbell TB (2004) Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 39(12):1852–1855.  https://doi.org/10.1086/426078CrossRefPubMedGoogle Scholar
  19. 19.
    Damania B (2004) Oncogenic gamma-herpesviruses: comparison of viral proteins involved in tumorigenesis. Nat Rev Microbiol 2(8):656–668CrossRefPubMedGoogle Scholar
  20. 20.
    Davis DA, Mishra S, Anagho HA, Aisabor AI, Shrestha P, Wang V, Takamatsu Y, Maeda K, Mitsuya H, Zeldis JB, Yarchoan R (2017) Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. Oncotarget 8(31):50342–50358, May 17Google Scholar
  21. 21.
    Decker LL, Shankar P, Khan G, Freeman RB, Dezube BJ, Lieberman J, Thorley-Lawson DA (1996) The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med 184(1):283–288CrossRefPubMedGoogle Scholar
  22. 22.
    Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST (2005) High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic/plasmablastic diffuse large B-cell lymphoma. LeukemiaGoogle Scholar
  23. 23.
    Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS malignancy consortium study. J Clin Oncol 24(9):1389–1394CrossRefPubMedGoogle Scholar
  24. 24.
    Dittmer DP (2003) Transcription profile of Kaposi’s Sarcoma-associated herpesvirus in primary Kaposi’s Sarcoma lesions as determined by real-time PCR arrays. Cancer Res 63(9):2010–2015PubMedGoogle Scholar
  25. 25.
    Dittmer DP, Damania B (2016) Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy. J Clin Invest 126(9):3165–3175.  https://doi.org/10.1172/JCI84418CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D (1998) A cluster of latently expressed genes in Kaposi’s sarcoma-associated herpesvirus. J Virol 72(10):8309–8315PubMedCentralPubMedGoogle Scholar
  27. 27.
    Dittmer DP, Damania B (2007) KSHV-associated disease in the AIDS patient. AIDS-associated viral oncogenesis. Editor: Craig Meyers, SpringerGoogle Scholar
  28. 28.
    Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J, Dong HY, Harris NL, Chan JK, Rees JW, Dogan A, Isaacson PG (2002) KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 100(9):3415–3418CrossRefPubMedGoogle Scholar
  29. 29.
    Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97(7):2130–2136CrossRefPubMedGoogle Scholar
  30. 30.
    Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96(8):4546–4551CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dupin N, Grandadam M, Calvez V, Gorin I, Aubin JT, Havard S, Lamy F, Leibowitch M, Huraux JM, Escande JP, Agut H (1995) Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi’s sarcoma. Lancet 345(8952):761–762CrossRefPubMedGoogle Scholar
  32. 32.
    El-Mallawany NK, Kamiyango W, Slone JS, Villiera J, Kovarik CL, Cox CM, Dittmer DP, Ahmed S, Schutze GE, Scheurer ME, Kazembe PN, Mehta PS (2016) Clinical factors associated with long-term complete remission versus poor response to chemotherapy in HIV-infected children and adolescents with Kaposi sarcoma receiving bleomycin and vincristine: a retrospective observational study. PLoS One 11(4):e0153335.  https://doi.org/10.1371/journal.pone.0153335CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Fakhari FD (2002) Charting latency transcripts in Kaposi’s sarcoma-associated herpesvirus by whole-genome real-time quantitative reverse transcription-PCR. J Virol 76(12)Google Scholar
  34. 34.
    Fan W, Bubman D, Chadburn A, Harrington WJ Jr, Cesarman E, Knowles DM (2005) Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol 79(2):1244–1251CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Farge D, Lebbe C, Marjanovic Z, Tuppin P, Mouquet C, Peraldi MN, Lang P, Hiesse C, Antoine C, Legendre C, Bedrossian J, Gagnadoux MF, Loirat C, Pellet C, Sheldon J, Golmard JL, Agbalika F, Schulz TF (1999) Human herpes virus-8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’ Ile de France (GCIF). Transplantation 67(9):1236–1242CrossRefPubMedGoogle Scholar
  36. 36.
    Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J (2011) The HIV protease inhibitor nelfinavir inhibits Kaposi’s sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 55(6):2696–2703.  https://doi.org/10.1128/AAC.01295-10CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS (1996) Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med 335(4):233–241CrossRefPubMedGoogle Scholar
  38. 38.
    Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G, Toomey NL, Shank NC, Cabral L, Barber GN, Harrington WJ Jr (2003) Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 101(6):2321–2327CrossRefPubMedGoogle Scholar
  39. 39.
    Gramolelli S, Weidner-Glunde M, Abere B, Viejo-Borbolla A, Bala K, Ruckert J, Kremmer E, Schulz TF (2015) Inhibiting the recruitment of PLCgamma1 to Kaposi’s sarcoma herpesvirus K15 protein reduces the invasiveness and angiogenesis of infected endothelial cells. PLoS Pathog 11(8):e1005105.  https://doi.org/10.1371/journal.ppat.1005105CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Grundhoff A, Ganem D (2004) Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113(1):124–136CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hahn AS, Kaufmann JK, Wies E, Naschberger E, Panteleev-Ivlev J, Schmidt K, Holzer A, Schmidt M, Chen J, Konig S, Ensser A, Myoung J, Brockmeyer NH, Sturzl M, Fleckenstein B, Neipel F (2012) The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma-associated herpesvirus. Nat Med 18(6):961–966.  https://doi.org/10.1038/nm.2805CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Hansen A, Henderson S, Lagos D, Nikitenko L, Coulter E, Roberts S, Gratrix F, Plaisance K, Renne R, Bower M, Kellam P, Boshoff C (2010) KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. Genes Dev 24(2):195–205.  https://doi.org/10.1101/gad.553410CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezube BJ, Fingeroth JD, Detmar M (2004) Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 36(7):683–685CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hosseinipour MC, Sweet KM, Xiong J, Namarika D, Mwafongo A, Nyirenda M, Chiwoko L, Kamwendo D, Hoffman I, Lee J, Phiri S, Vahrson W, Damania B, Dittmer DP (2014) Viral profiling identifies multiple subtypes of Kaposi’s sarcoma. MBio 5(5):e01614–e01633.  https://doi.org/10.1128/mBio.01633-14CrossRefGoogle Scholar
  45. 45.
    Host KM, Horner MJ, van der Gronde T, Moses A, Phiri S, Dittmer DP, Damania B, Gopal S (2017) Kaposi’s sarcoma in Malawi: a continued problem for HIV-positive and HIV-negative individuals. AIDS 31(2):318–319.  https://doi.org/10.1097/QAD.0000000000001341CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R, Kellam P (2003) Kaposi’s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100(18):10399–10404CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Kaaya SF, Leshabari MT, Mbwambo JK (1998) Risk behaviors and vulnerability to HIV infection among Tanzanian youth. J Health Popul Dev Ctries 1(2):51–60PubMedGoogle Scholar
  48. 48.
    Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106(5):1538–1543CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kaposi M (1872) Idiopatisches multiples Pigmentsarkom der Haut. Arch Dermatol Syphillis 4:265–273CrossRefGoogle Scholar
  50. 50.
    Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D (1996) The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma- associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 2(8):918–924CrossRefPubMedGoogle Scholar
  51. 51.
    Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, Carbone A (2003) Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101(10):4115–4121CrossRefPubMedGoogle Scholar
  52. 52.
    Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, Crosby K, Proper J, Weeden W, Miller TE, Chatis P, Egorin MJ, Tahan SR, Dezube BJ (2005) Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J Clin Oncol 23(5):982–989CrossRefPubMedGoogle Scholar
  53. 53.
    Krown SE, Lee JY, Dittmer DP, Consortium AM (2008) More on HIV-associated Kaposi’s sarcoma. N Engl J Med 358(5):535–536; author reply 536.  https://doi.org/10.1056/nejmc072994
  54. 54.
    Labo N, Miley W, Benson CA, Campbell TB, Whitby D (2015) Epidemiology of Kaposi’s sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. AIDS 29(10):1217–1225.  https://doi.org/10.1097/QAD.0000000000000682CrossRefPubMedGoogle Scholar
  55. 55.
    Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, McMahon M, Ganem D (2002) De novo infection and serial transmission of Kaposi’s sarcoma-associated herpesvirus in cultured endothelial cells. J Virol 76(5):2440–2448CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Li H, Komatsu T, Dezube BJ, Kaye KM (2002) The Kaposi’s sarcoma-associated herpesvirus K12 transcript from a primary effusion lymphoma contains complex repeat elements, is spliced, and initiates from a novel promoter. J Virol 76(23):11880–11888CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, Rodriguez-Chavez IR, Pittaluga S, Tosato G, Yarchoan R (2003) A pilot study of cidofovir in patients with kaposi sarcoma. J Infect Dis 187(1):149–153CrossRefPubMedGoogle Scholar
  58. 58.
    Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS (2010) KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115(4):887–895.  https://doi.org/10.1182/blood-2009-08-236745CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH (1998) Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 338(14):948–954CrossRefGoogle Scholar
  60. 60.
    Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340(14):1063–1070CrossRefPubMedGoogle Scholar
  61. 61.
    Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA (2003) Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32(5):527–533CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    McCormick C, Ganem D (2005) The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307(5710):739–741CrossRefPubMedGoogle Scholar
  63. 63.
    Mendez JC, Procop GW, Espy MJ, Smith TF, McGregor CG, Paya CV (1999) Relationship of HHV8 replication and Kaposi’s sarcoma after solid organ transplantation. Transplantation 67(8):1200–1201CrossRefPubMedGoogle Scholar
  64. 64.
    Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS (2003) Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3(1):23–36CrossRefPubMedGoogle Scholar
  65. 65.
    Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, Hoover DR, Parry JP, Conley LJ, Jaffe HW, Chang Y (1996) Kaposi’s sarcoma-associated herpesvirus infection prior to onset of Kaposi’s sarcoma. Aids 10(2):175–180CrossRefPubMedGoogle Scholar
  66. 66.
    Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, Griffith DJ, Wait CL, Druker BJ, Heinrich MC, Nelson JA, Fruh K (2002) Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c- kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 76(16):8383–8399CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM (1996) Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88(2):645–656Google Scholar
  68. 68.
    Naranatt PP, Krishnan HH, Svojanovsky SR, Bloomer C, Mathur S, Chandran B (2004) Host gene induction and transcriptional reprogramming in Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 64(1):72–84CrossRefPubMedGoogle Scholar
  69. 69.
    Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16(7):2445–2451CrossRefPubMedGoogle Scholar
  70. 70.
    Olp LN, Jeanniard A, Marimo C, West JT, Wood C (2015) Whole-genome sequencing of Kaposi’s sarcoma-associated herpesvirus from zambian Kaposi’s sarcoma biopsy specimens reveals unique viral diversity. J Virol 89(24):12299–12308.  https://doi.org/10.1128/JVI.01712-15CrossRefPubMedCentralPubMedGoogle Scholar
  71. 71.
    Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, Chang Y (2000) Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol 156(3):743–749CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, Toledano C, Morel P, Verola O, Dosquet C, Hamel Y, Calvo F, Rabian C, Lebbe C (2006) Kaposi’s sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi’s sarcoma. J Invest Dermatol 126(3):621–627CrossRefPubMedGoogle Scholar
  73. 73.
    Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, Pittaluga S, O’Mahony D, Whitby D, Tosato G, Steinberg SM, Little RF, Yarchoan R (2013) Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 122(26):4189–4198.  https://doi.org/10.1182/blood-2013-08-519959CrossRefPubMedCentralPubMedGoogle Scholar
  74. 74.
    Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, Whitby D, Pittaluga S, Jaffe ES, Millo C, Tosato G, Little RF, Steinberg SM, Sereti I, Yarchoan R (2016) Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated Inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin Infect Dis 62(6):730–738.  https://doi.org/10.1093/cid/civ996CrossRefPubMedGoogle Scholar
  75. 75.
    Poole LJ, Yu Y, Kim PS, Zheng QZ, Pevsner J, Hayward GS (2002) Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi’s sarcoma-associated herpesvirus. J Virol 76(7):3395–3420CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, Biggar RJ, Zhuang Z (1997) Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med 336(14):988–993CrossRefPubMedGoogle Scholar
  77. 77.
    Rappocciolo G, Jenkins FJ, Hensler HR, Piazza P, Jais M, Borowski L, Watkins SC, Rinaldo CR Jr (2006) DC-SIGN is a receptor for human herpesvirus 8 on dendritic cells and macrophages. J Immunol 176(3):1741–1749CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19(8):2171–2178CrossRefGoogle Scholar
  79. 79.
    Renne R, Barry C, Dittmer D, Compitello N, Brown PO, Ganem D (2001) Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus. J Virol 75(1):458–468CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y (2001) Kaposi’s sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 75(1):429–438CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    De Rosa G, Barra E, Guarino M, Gentile R (1989) Multicentric Castleman’s disease in association with Kaposi’s sarcoma. Appl Pathol 7(2):105–110PubMedGoogle Scholar
  82. 82.
    Roy D, Sin SH, Lucas A, Venkataramanan R, Wang L, Eason A, Chavakula V, Hilton IB, Tamburro KM, Damania B, Dittmer DP (2013) mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 73(7):2235–2246.  https://doi.org/10.1158/0008-5472.CAN-12-1851CrossRefPubMedCentralPubMedGoogle Scholar
  83. 83.
    Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS (1996) Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93(25):14862–14867CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, Ganem D (1999) A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi’s sarcoma-associated herpesvirus. J Virol 73(7):5722–5730PubMedCentralPubMedGoogle Scholar
  85. 85.
    Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS (2009) The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113(1):254–263.  https://doi.org/10.1182/blood-2008-02-140020CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    Scott D, Cabral L, Harrington WJ Jr (2001) Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol 66(2):148–150CrossRefPubMedGoogle Scholar
  87. 87.
    Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8(3):225–232CrossRefPubMedGoogle Scholar
  88. 88.
    Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R, North American ACCoR, Design of the International Epidemiologic Databases to Evaluate A (2015) Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med 163(7):507–518.  https://doi.org/10.7326/m14-2768CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, Henry D, Harrington WJ Jr, Damania BA, Dittmer DP (2007) Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 109(5):2165–2173.  https://doi.org/10.1182/blood-2006-06-028092CrossRefPubMedCentralPubMedGoogle Scholar
  90. 90.
    Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86(4):1276–1280PubMedGoogle Scholar
  91. 91.
    Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352(13):1317–1323CrossRefPubMedGoogle Scholar
  92. 92.
    Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT (1997) Kaposi’s sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71(1):715–719PubMedCentralPubMedGoogle Scholar
  93. 93.
    Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP (2004) The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 64(14):4790–4799CrossRefPubMedGoogle Scholar
  94. 94.
    Uldrick TS, Polizzotto MN, Aleman K, O’Mahony D, Wyvill KM, Wang V, Marshall V, Pittaluga S, Steinberg SM, Tosato G, Whitby D, Little RF, Yarchoan R (2011) High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 117(26):6977–6986.  https://doi.org/10.1182/blood-2010-11-317610CrossRefPubMedCentralPubMedGoogle Scholar
  95. 95.
    Uldrick TS, Wyvill KM, Kumar P, O’Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R (2012) Phase II study of bevacicumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol 30(13):1476–1483.  https://doi.org/10.1200/JCO.2011.39.6853CrossRefPubMedCentralPubMedGoogle Scholar
  96. 96.
    Vieira J, Huang ML, Koelle DM, Corey L (1997) Transmissible Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi’s sarcoma. J Virol 71(9):7083–7087PubMedCentralPubMedGoogle Scholar
  97. 97.
    Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi’s sarcoma-associated herpesvirus. Cancer Res 66(7):3658–3666CrossRefPubMedGoogle Scholar
  98. 98.
    Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C (2004) Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36(7):687–693CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Wang L, Wakisaka N, Tomlinson CC, DeWire SM, Krall S, Pagano JS, Damania B (2004) The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Research 64(8):2774–2781, Apr 15CrossRefPubMedGoogle Scholar
  100. 100.
    Wang L, Wakisaka N, Tomlinson CC, DeWire S, Krall S, Pagano JS, Damania B (2004) The Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV8) K1 protein induces expression of angiogenic and invasion factors. Cancer ResearchGoogle Scholar
  101. 101.
    Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS et al (1995) Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 346(8978):799–802CrossRefPubMedGoogle Scholar
  102. 102.
    Whitby D, Luppi M, Barozzi P, Boshoff C, Weiss RA, Torelli G (1998) Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 90(5):395–397CrossRefPubMedGoogle Scholar
  103. 103.
    Yu L, Tu M, Cortes J, Xu-Monette ZY, Miranda RN, Zhang J, Orlowski RZ, Neelapu S, Boddu PC, Akosile MA, Uldrick TS, Yarchoan R, Medeiros LJ, Li Y, Fajgenbaum DC, Young KH (2017) Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood 129(12):1658–1668.  https://doi.org/10.1182/blood-2016-11-748855CrossRefPubMedCentralPubMedGoogle Scholar
  104. 104.
    Zhang Z, Chen W, Sanders MK, Brulois KF, Dittmer DP, Damania B (2016) The K1 protein of Kaposi’s sarcoma-associated herpesvirus augments viral lytic replication. J Virol 90(17):7657–7666.  https://doi.org/10.1128/JVI.03102-15CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Microbiology & ImmunologyLineberger Comprehensive Cancer Center, University of North CarolinaChapel HillUSA

Personalised recommendations